Prestige Consumer Healthcare (PBH) EBITDA Margin (2010 - 2025)

Prestige Consumer Healthcare's EBITDA Margin history runs 16 years deep, the most recent figure standing at 16.96% for Q4 2025.

• In Q4 2025, EBITDA Margin rose 63.0% year-over-year to 16.96%; the TTM figure through Dec 2025 stood at 17.8% (down 29.0% YoY), while the FY2025 annual figure was 18.58%, up 24.0% from the prior year.
• EBITDA Margin was 16.96% for Q4 2025 at Prestige Consumer Healthcare, up from 15.64% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 21.4% in Q4 2023 to a low of 84.87% in Q1 2023.
• Historically, EBITDA Margin has averaged 12.97% across 5 years, with a median of 17.57% in 2025.
• The sharpest annual moves came in 2023 and 2024: EBITDA Margin slumped 10595 bps in 2023, then soared 10058 bps in 2024.
• A 5-year view of EBITDA Margin shows it stood at 18.74% in 2021, then gained by 14 bps to 21.39% in 2022, then grew by 0 bps to 21.4% in 2023, then declined by 24 bps to 16.33% in 2024, then increased by 4 bps to 16.96% in 2025.
• The last three EBITDA Margin figures came in at 16.96% (Q4 2025), 15.64% (Q3 2025), and 21.19% (Q2 2025), per Business Quant data.